The U.S. Food and Drug Administration said on Friday it had approved a treatment for a rare blood disorder from Celgene Corp, which is in the process of being bought by Bristol-Myers Squibb Co. Reblozyl, which has been jointly developed by Celgene and Acceleron Pharma Inc, is meant for treatment of anemia in patients with beta thalassemia, who require regular red blood cell transfusions. Beta thalassemia is an inherited disorder that reduces the production of hemoglobin in blood, which can lead to lack of oxygen in many parts of the body and anemia, the FDA said. …read more
Source:: Yahoo Finance
